Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 2.24B 2.02B 1.87B 1.69B 3.19B 210B 3.29B 22.42B 8.91B 112B 8.4B 8.22B 358B P/E 2026 *
-4.04x
P/E 2027 * -4.23x
Enterprise Value 1.68B 1.52B 1.4B 1.27B 2.4B 158B 2.47B 16.83B 6.69B 84.45B 6.31B 6.17B 269B EV / Sales 2026 *
41.7x
EV / Sales 2027 * 43.2x
Free-Float
98.23%
Yield 2026 *
-
Yield 2027 * -
1 day-4.60%
1 week-2.01%
Current month-14.90%
1 month-14.47%
3 months+4.25%
6 months+8.88%
Current year-16.14%
1 week 3.26
Extreme 3.265
3.87
1 month 3.26
Extreme 3.265
4.52
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
5.24
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
21.19
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 01/01/2026
Director of Finance/CFO 48 20/11/2024
Chief Tech/Sci/R&D Officer 57 06/04/2026
Director TitleAgeSince
Director/Board Member 44 04/11/2013
Director/Board Member 62 04/11/2013
Director/Board Member 37 01/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
11/3/26 A Sell

Founder

-40,000 0.0067%
11/2/26 A Free

Chairman

156,658 0.0262%
10/6/26 A Sell

Founder

-50,000 0.0093%
Change 5-day change 1-year change 3-year change Capi.($)
-4.60%-2.01%-26.24%-41.17% 2.24B
+1.10%+1.03%+62.53%+70.47% 67.53B
+1.28%+8.71%+13.96%+92.70% 60.74B
+0.36%-0.95%+20.09%+98.45% 55.66B
+0.20%+8.81%+11.63%+111.91% 47.97B
-0.94%+2.57%+23.00%+40.28% 45.24B
-1.40%+0.31%+170.69%+806.84% 39.08B
+1.21%+4.75%+27.30%+52.81% 35.34B
-0.87%-2.89%+79.60%+56.33% 33.45B
-1.59%+9.21%-38.90%+396.99% 26.49B
Average -0.50%+1.68%+34.37%+168.56% 41B
Weighted average by Cap. +0.14%+2.83%+41.08%+166.21%

Financials

2026 *2027 *
Net sales 40.32M 36.46M 33.66M 30.46M 57.48M 3.79B 59.21M 404M 161M 2.03B 151M 148M 6.45B 44.2M 39.97M 36.9M 33.4M 63.02M 4.16B 64.91M 443M 176M 2.22B 166M 162M 7.07B
Net income -479M -433M -400M -362M -683M -45B -703M -4.8B -1.91B -24.06B -1.8B -1.76B -76.58B -494M -447M -413M -373M -705M -46.47B -726M -4.95B -1.97B -24.84B -1.86B -1.82B -79.08B
Net Debt -558M -504M -465M -421M -795M -52.42B -819M -5.59B -2.22B -28.02B -2.09B -2.05B -89.2B -326M -295M -272M -247M -465M -30.68B -479M -3.27B -1.3B -16.4B -1.22B -1.2B -52.2B
Projected Income Statement - Annual - Recursion Pharmaceuticals, Inc.
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
12/11/26 $3.435 -4.32% 12,205,980
11/11/26 $3.590 +1.13% 16,595,407
10/11/26 $3.550 -6.70% 19,099,840
09/11/26 $3.805 +8.10% 20,366,666
06/11/26 $3.520 +0.57% 15,585,949
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Recursion Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.590USD
Average target price
7.317USD
Spread / Average Target
+103.81%
  1. Stock Market
  2. Stocks
  3. RXRX Stock